Trade Names:Bontril PDM- Tablets 35 mg
Trade Names:Bontril Slow-Release- Tablets 35 mg
Trade Names:Melfiat-105 Unicelles- Tablets 35 mg
Trade Names:Prelu-2- Capsules, sustained-release 105 mg
May stimulate satiety center in brain, causing appetite suppression.
Phendimetrazine is readily absorbed.
Phendimetrazine metabolism is hepatic. Some of the drug is metabolized to phenmetrazine and phendimetrazine-N-oxide.
Excretion is via the kidneys and is increased by acidifying the urine. The t ½ is 1.9 h (immediate-release) and 9.8 h (slow-release).
Short-term (few weeks) adjunct to diet plan to reduce weight.
Hypersensitivity to sympathomimetic amines; pregnancy; advanced arteriosclerosis; symptomatic CV disease; moderate to severe hypertension; hyperthyroidism; glaucoma; agitated states; history of drug abuse; during or within 14 days following the administration of an MAOI.
PO Tablets or capsules: 35 mg 2 or 3 times daily before meals; sustained-release capsules: 105 mg once daily in the morning before breakfast.
Swallow sustained-release capsule whole. Do not crush, chew, or open capsule.
Store at controlled room temperature (59° to 86°F).
May decrease hypotensive effect of guanethidine.MAOIs (eg, phenelzine); furazolidone
May cause hypertensive crisis and intracranial hemorrhage.Selective serotonin reuptake inhibitors (eg, fluoxetine)
Sympathomimetic effects of phendimetrazine and risk of “serotonin syndrome” may be increased.
None well documented.
Palpitation; tachycardia, hypertension.
Overstimulation; restlessness; dizziness; insomnia; euphoria; dysphoria; tremor; headache; psychosis.
Dry mouth; unpleasant taste; diarrhea; constipation.
Impotence; changes in libido.
Do not use in women who are pregnant or may become pregnant.
Safety and efficacy not established in children younger than 12 yr of age.
Use with caution in patients with glaucoma, hypertension, diabetes mellitus.
Psychological and physical dependence may occur with continued use; this class of drugs has been extensively abused.
Tolerance to the anorectic effect usually develops within a few weeks.
Restlessness, tremor, hyperreflexia, rapid respiration, confusion, assaultiveness, hallucinations, panic states, fatigue, depression, arrhythmias, hypertension, hypotension, circulatory collapse, nausea, vomiting, diarrhea, abdominal cramps, convulsions, coma, death.
Copyright © 2009 Wolters Kluwer Health.